Gi Nell Elliott
About Gi Nell Elliott
Gi Nell Elliott serves as the Associate Director of Translational Data Science at Nimbus Therapeutics, a position she has held since 2024. She has a strong academic background with a Ph.D. in Computational and Systems Biology from Washington University School of Medicine and extensive experience in bioinformatics across several prominent companies.
Work at Nimbus
Gi Nell Elliott serves as the Associate Director of Translational Data Science at Nimbus Therapeutics. She has held this position since 2024, contributing to the company's focus on innovative drug discovery and development. Nimbus Therapeutics is located in Boston, Massachusetts, and operates in a hybrid work environment. In her role, Elliott applies her expertise in data science to facilitate the translation of scientific research into therapeutic solutions.
Education and Expertise
Gi Nell Elliott earned her Doctor of Philosophy (Ph.D.) in Computational and Systems Biology from Washington University School of Medicine in St. Louis, where she studied from 2008 to 2015. Prior to this, she obtained a Bachelor's Degree in Bioinformatics from St. Edward's University, completing her studies from 2003 to 2007. Her educational background provides a strong foundation for her work in bioinformatics and data science.
Background
Gi Nell Elliott has a diverse professional background in the field of bioinformatics. She began her career as a Bioinformatics Investigator at Novartis Institutes for BioMedical Research (NIBR), where she worked from 2015 to 2021. Following her tenure at Novartis, she served as Principal Scientist in Bioinformatics at Foghorn Therapeutics, Inc. from 2021 to 2024. This progression highlights her extensive experience in the biomedical research sector.
Professional Experience
Elliott has accumulated significant experience in the bioinformatics field through her various roles. At Novartis Institutes for BioMedical Research, she focused on bioinformatics applications in drug discovery. Her subsequent role at Foghorn Therapeutics involved leading bioinformatics initiatives, further enhancing her expertise. This trajectory reflects her commitment to advancing the field of translational data science.